Table 3.
Plasma and urinary glycation, oxidation, and nitration free adduct in plasma filtrate
| Amino acid | Plasma (nM) | Urine (nmol/mg creatinine) | ||||
|---|---|---|---|---|---|---|
| Healthy controls | ASD | P value | Healthy controls | ASD | P value | |
| FL | 1489 (987–1863) | 751 (361–1.570) | 0.047 | 56.7 (33.8–128.7) | 90.8 (42.4–167.9) | |
| CML | 807 (587–1051) | 853 (219–1222) | 26.2 (19.7–34.7) | 33.1 (26.6–42.6) | 0.016 | |
| CEL | 402 (298–477) | 420 (310–599) | 0.435 (0.202–0.848) | 0.472 (0.180–0.940) | ||
| G-H1 | 0.819 (0.553–1.26) | 0.527 (0.366–0.959) | 0.037 | 1.88 (1.11–3.04) | 2.57 (1.53–3.75) | 0.024 |
| MG-H1 | 271 (176–475) | 335 (213–500) | 18.6 (8.00–27.4) | 24.5 (9.14–37.6) | ||
| 3DG-H | 413 (303–637) | 360 (280–434) | 2.06 (0.587–4.38) | 2.92 (1.09–6.26) | ||
| CMA | 9.18 (6.67–12.5) | 17.7 (13.2–24.8) | 0.00052** | 1.46 (0.636–1.97) | 1.78 (1.14–2.91) | 0.037 |
| GSP | 12.8 (7.4–17.1) | 12.9 (9.3–22.0) | 1.58 (1.15–1.98) | 1.53 (1.20–1.98) | ||
| MOLD | 1.79 (0.800–3.42) | 1.10 (0.503–0.2.21) | 0.025 (0.013–0.050) | 0.040 (0.017–0.068) | 0.027 | |
| Pyrraline | 22.0 (12.2–30.4) | 24.2 (19.4–40.6) | 20.6 (14.9–44.2) | 34.2 (22.7–72.5) | 0.047 | |
| DT | 0.501 (0.286–0.771) | 0.676 (0.500–0.847) | 0.070 (0.058–0.085) | 0.086 (0.075–0.109) | 0.0022* | |
| NFK | 15.2 (12.5–18.1) | 11.3 (6.23–14.3) | 0.030 | 0.117 (0.084–0.231) | 0.179 (0.107–0.238) | 0.037 |
| AASA | 19.7 (16.9–29.1) | 30.6 (21.1–46.4) | 0.0063 | 1.08 (0.805–2.76) | 1.80 (1.13–2.89) | 0.040 |
| GSA | 73.9 (53.2–129) | 109 (80.1–203) | 0.039 | 17.3 (13.2–22.7) | 34.5 (12.7–48.0) | 0.0018* |
| 3-NT | 1.10 (0.90–1.26) | 1.17 (0.79–1.58) | 0.0044 (0.001–0.010) | 0.0077 (0.003–0.014) | ||
Data are median (lower – upper quartile); healthy controls, n = 21–31, and ASD, n = 27–38. Significance (Mann-Whitney U)
*P < 0.05 after Bonferroni correction of 15 applied